Atopic Dermatitis Drugs Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Atopic Dermatitis Drugs Market to 2027 - Global Analysis and Forecasts by Route of Administration (Topical, Injectable, Oral); Drug Class (Topical antibiotics, Topical antihistamines, Topical corticosteroids, Topical Moisturizers/Emollients, Topical calcineurin inhibitors, Immunomodulators, Off-Label Therapies, Systemic Agents, PDE4 inhibitor, Interleukin inhibitor, Interleukin inhibitor) and Geography

Report Code: TIPRE00004422 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Atopic Dermatitis is chronic skin condition which is also known as atopic eczema. It is a type of infection (bacteria, fungi, yeast and viruses) of skin which result in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas and also suffer from asthma, hay fever. The eczema is more common in infants and children then adults and very less in the midlife. The condition can be treated with topical steroids, topical calcineurin inhibitors (TCIs) and phototherapy there are also some Systemic drug (i.e. methotrexate, cyclosporine, and mycophenolate mofetil) used to treat the flares. The researchers have developed new drug which are currently in clinical trial pipeline.

MARKET DYNAMICS
Increasing incidence of atopic dermatitis, higher treatment compliance, growing prevalence of food allergies exacerbating atopic dermatitis, growing access to treatment in various developing countries and favorable reimbursement policies in some countries are driving the market growth of atopic dermatitis treatment worldwide. However, generic erosion, poor awareness among the patient population and adverse effects associated with the use of medication is hampering the growth of atopic dermatitis treatment market.

MARKET SCOPE
The "Global Atopic Dermatitis Drug Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of atopic dermatitis drug market with detailed market segmentation by route of administration, drug class, and geography. The global atopic dermatitis drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Atopic Dermatitis Drug market players and offers key trends and opportunities in the market

MARKET SEGMENTATION
The global atopic dermatitis drug market is segmented on the basis of Route of administration and Drug class. Based on route of administration, the market is segmented as topical, injectable and oral. On the basis of drug class, the global atopic dermatitis market is segmented into topical antibiotics, topical antihistamines, topical corticosteroids, topical moisturizers/emollients, topical calcineurin inhibitor, and immunomodulators, off-label therapies, systemic agent, PDE4 inhibitors, and interleukin inhibitors.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Atopic Dermatitis Drug market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Atopic Dermatitis Drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Atopic Dermatitis Drug market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the atopic dermatitis drug market in these regions.

MARKET PLAYERS
The reports cover key developments in the Atopic Dermatitis Drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from atopic dermatitis drug market are anticipated to lucrative growth opportunities in the future with the rising demand for atopic dermatitis drug in the global market. Below mentioned is the list of few companies engaged in the atopic dermatitis drug market.

The report also includes the profiles of key atopic dermatitis drug market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • MYLAN
  • LEO PHARMA
  • BAYER HEALTHCARE
  • ENCORE DERMATOLOGY
  • NOVARTIS AG
  • BAUSCH HEALTH
  • ASTELLAS PHARMA INC
  • MEDA AB
  • ENCORE DERMATOLOGY
  • SANOFI
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Atopic Dermatitis Drugs Market - By Route of Administration
1.3.2 Atopic Dermatitis Drugs Market - By Drug Class
1.3.3 Atopic Dermatitis Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. ATOPIC DERMATITIS DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ATOPIC DERMATITIS DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ATOPIC DERMATITIS DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ATOPIC DERMATITIS DRUGS - GLOBAL MARKET OVERVIEW
6.2. ATOPIC DERMATITIS DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ATOPIC DERMATITIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
7.1. OVERVIEW
7.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
7.3. TOPICAL
7.3.1. Overview
7.3.2. Topical Market Forecast and Analysis
7.4. INJECTABLE
7.4.1. Overview
7.4.2. Injectable Market Forecast and Analysis
7.5. ORAL
7.5.1. Overview
7.5.2. Oral Market Forecast and Analysis
8. ATOPIC DERMATITIS DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. TOPICAL ANTIBIOTICS
8.3.1. Overview
8.3.2. Topical antibiotics Market Forecast and Analysis
8.4. TOPICAL ANTIHISTAMINES
8.4.1. Overview
8.4.2. Topical antihistamines Market Forecast and Analysis
8.5. TOPICAL CORTICOSTEROIDS
8.5.1. Overview
8.5.2. Topical corticosteroids Market Forecast and Analysis
8.6. TOPICAL MOISTURIZERS/EMOLLIENTS
8.6.1. Overview
8.6.2. Topical moisturizers/emollients Market Forecast and Analysis
8.7. TOPICAL CALCINEURIN INHIBITORS
8.7.1. Overview
8.7.2. Topical calcineurin inhibitors Market Forecast and Analysis
8.8. IMMUNOMODULATORS
8.8.1. Overview
8.8.2. Immunomodulators Market Forecast and Analysis
8.9. OFF-LABEL THERAPIES
8.9.1. Overview
8.9.2. off-label therapies Market Forecast and Analysis
8.10. SYSTEMIC AGENTS
8.10.1. Overview
8.10.2. Systemic agents Market Forecast and Analysis
8.11. PDE4 INHIBITOR
8.11.1. Overview
8.11.2. PDE4 inhibitor Market Forecast and Analysis
8.12. INTERLEUKIN INHIBITOR
8.12.1. Overview
8.12.2. Interleukin inhibitor Market Forecast and Analysis

9. ATOPIC DERMATITIS DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Atopic Dermatitis Drugs Market Overview
9.1.2 North America Atopic Dermatitis Drugs Market Forecasts and Analysis
9.1.3 North America Atopic Dermatitis Drugs Market Forecasts and Analysis - By Route of Administration
9.1.4 North America Atopic Dermatitis Drugs Market Forecasts and Analysis - By Drug Class
9.1.5 North America Atopic Dermatitis Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Atopic Dermatitis Drugs Market
9.1.5.1.1 United States Atopic Dermatitis Drugs Market by Route of Administration
9.1.5.1.2 United States Atopic Dermatitis Drugs Market by Drug Class
9.1.5.2 Canada Atopic Dermatitis Drugs Market
9.1.5.2.1 Canada Atopic Dermatitis Drugs Market by Route of Administration
9.1.5.2.2 Canada Atopic Dermatitis Drugs Market by Drug Class
9.1.5.3 Mexico Atopic Dermatitis Drugs Market
9.1.5.3.1 Mexico Atopic Dermatitis Drugs Market by Route of Administration
9.1.5.3.2 Mexico Atopic Dermatitis Drugs Market by Drug Class
9.2. EUROPE
9.2.1 Europe Atopic Dermatitis Drugs Market Overview
9.2.2 Europe Atopic Dermatitis Drugs Market Forecasts and Analysis
9.2.3 Europe Atopic Dermatitis Drugs Market Forecasts and Analysis - By Route of Administration
9.2.4 Europe Atopic Dermatitis Drugs Market Forecasts and Analysis - By Drug Class
9.2.5 Europe Atopic Dermatitis Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Atopic Dermatitis Drugs Market
9.2.5.1.1 Germany Atopic Dermatitis Drugs Market by Route of Administration
9.2.5.1.2 Germany Atopic Dermatitis Drugs Market by Drug Class
9.2.5.2 France Atopic Dermatitis Drugs Market
9.2.5.2.1 France Atopic Dermatitis Drugs Market by Route of Administration
9.2.5.2.2 France Atopic Dermatitis Drugs Market by Drug Class
9.2.5.3 Italy Atopic Dermatitis Drugs Market
9.2.5.3.1 Italy Atopic Dermatitis Drugs Market by Route of Administration
9.2.5.3.2 Italy Atopic Dermatitis Drugs Market by Drug Class
9.2.5.4 Spain Atopic Dermatitis Drugs Market
9.2.5.4.1 Spain Atopic Dermatitis Drugs Market by Route of Administration
9.2.5.4.2 Spain Atopic Dermatitis Drugs Market by Drug Class
9.2.5.5 United Kingdom Atopic Dermatitis Drugs Market
9.2.5.5.1 United Kingdom Atopic Dermatitis Drugs Market by Route of Administration
9.2.5.5.2 United Kingdom Atopic Dermatitis Drugs Market by Drug Class
9.2.5.6 Rest of Europe Atopic Dermatitis Drugs Market
9.2.5.6.1 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration
9.2.5.6.2 Rest of Europe Atopic Dermatitis Drugs Market by Drug Class
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Atopic Dermatitis Drugs Market Overview
9.3.2 Asia-Pacific Atopic Dermatitis Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Atopic Dermatitis Drugs Market Forecasts and Analysis - By Route of Administration
9.3.4 Asia-Pacific Atopic Dermatitis Drugs Market Forecasts and Analysis - By Drug Class
9.3.5 Asia-Pacific Atopic Dermatitis Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Atopic Dermatitis Drugs Market
9.3.5.1.1 Australia Atopic Dermatitis Drugs Market by Route of Administration
9.3.5.1.2 Australia Atopic Dermatitis Drugs Market by Drug Class
9.3.5.2 China Atopic Dermatitis Drugs Market
9.3.5.2.1 China Atopic Dermatitis Drugs Market by Route of Administration
9.3.5.2.2 China Atopic Dermatitis Drugs Market by Drug Class
9.3.5.3 India Atopic Dermatitis Drugs Market
9.3.5.3.1 India Atopic Dermatitis Drugs Market by Route of Administration
9.3.5.3.2 India Atopic Dermatitis Drugs Market by Drug Class
9.3.5.4 Japan Atopic Dermatitis Drugs Market
9.3.5.4.1 Japan Atopic Dermatitis Drugs Market by Route of Administration
9.3.5.4.2 Japan Atopic Dermatitis Drugs Market by Drug Class
9.3.5.5 South Korea Atopic Dermatitis Drugs Market
9.3.5.5.1 South Korea Atopic Dermatitis Drugs Market by Route of Administration
9.3.5.5.2 South Korea Atopic Dermatitis Drugs Market by Drug Class
9.3.5.6 Rest of Asia-Pacific Atopic Dermatitis Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Atopic Dermatitis Drugs Market by Route of Administration
9.3.5.6.2 Rest of Asia-Pacific Atopic Dermatitis Drugs Market by Drug Class
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Atopic Dermatitis Drugs Market Overview
9.4.2 Middle East and Africa Atopic Dermatitis Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Atopic Dermatitis Drugs Market Forecasts and Analysis - By Route of Administration
9.4.4 Middle East and Africa Atopic Dermatitis Drugs Market Forecasts and Analysis - By Drug Class
9.4.5 Middle East and Africa Atopic Dermatitis Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Atopic Dermatitis Drugs Market
9.4.5.1.1 South Africa Atopic Dermatitis Drugs Market by Route of Administration
9.4.5.1.2 South Africa Atopic Dermatitis Drugs Market by Drug Class
9.4.5.2 Saudi Arabia Atopic Dermatitis Drugs Market
9.4.5.2.1 Saudi Arabia Atopic Dermatitis Drugs Market by Route of Administration
9.4.5.2.2 Saudi Arabia Atopic Dermatitis Drugs Market by Drug Class
9.4.5.3 U.A.E Atopic Dermatitis Drugs Market
9.4.5.3.1 U.A.E Atopic Dermatitis Drugs Market by Route of Administration
9.4.5.3.2 U.A.E Atopic Dermatitis Drugs Market by Drug Class
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Atopic Dermatitis Drugs Market Overview
9.5.2 South and Central America Atopic Dermatitis Drugs Market Forecasts and Analysis
9.5.3 South and Central America Atopic Dermatitis Drugs Market Forecasts and Analysis - By Route of Administration
9.5.4 South and Central America Atopic Dermatitis Drugs Market Forecasts and Analysis - By Drug Class
9.5.5 South and Central America Atopic Dermatitis Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Atopic Dermatitis Drugs Market
9.5.5.1.1 Brazil Atopic Dermatitis Drugs Market by Route of Administration
9.5.5.1.2 Brazil Atopic Dermatitis Drugs Market by Drug Class
9.5.5.2 Argentina Atopic Dermatitis Drugs Market
9.5.5.2.1 Argentina Atopic Dermatitis Drugs Market by Route of Administration
9.5.5.2.2 Argentina Atopic Dermatitis Drugs Market by Drug Class
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ATOPIC DERMATITIS DRUGS MARKET, KEY COMPANY PROFILES
11.1. MYLAN
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. LEO PHARMA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BAYER HEALTHCARE
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ENCORE DERMATOLOGY
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. NOVARTIS AG
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. BAUSCH HEALTH
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ASTELLAS PHARMA INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MEDA AB
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ENCORE DERMATOLOGY
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SANOFI
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. MYLAN
2. LEO PHARMA
3. BAYER HEALTHCARE
4. ENCORE DERMATOLOGY
5. NOVARTIS AG
6. BAUSCH HEALTH
7. ASTELLAS PHARMA INC
8. MEDA AB
9. ENCORE DERMATOLOGY
10. SANOFI
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book